Merck & Company, Inc. Press Releases

MRK 
$58.96
*  
0.44
0.75%
Get MRK Alerts
*Delayed - data as of Jul. 31, 2015  -  Find a broker to begin trading MRK now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By

ALK’s partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal
6/9/2015 7:01:00 PM - Business Wire
▲0.31 % Price Change since this news event. The Volume Ratio is 1.17.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


TECOS, Merck’s Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes
6/8/2015 4:30:00 PM - Business Wire
▲0.15 % Price Change since this news event. The Volume Ratio is 0.75.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






Results from Investigational IMPROVE-IT Study of VYTORIN® (ezetimibe and simvastatin) Published in the New England Journal of Medicine
6/3/2015 5:00:00 PM - Business Wire
▼-2.64 % Price Change since this news event. The Volume Ratio is 0.98.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Non-Small Cell Lung Cancer, and Grants Priority Review
6/1/2015 4:34:00 PM - Business Wire
▼-3.23 % Price Change since this news event. The Volume Ratio is 0.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies
6/1/2015 8:30:00 AM - Business Wire
▼-3.46 % Price Change since this news event. The Volume Ratio is 1.11.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






SIRFLOX Study Presented at ASCO 2015 Annual Meeting
5/30/2015 5:00:00 PM - PR Newswire




New Findings Show Durable Anti-Tumor Activity with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status
5/29/2015 2:06:00 PM - Business Wire
▼-1.90 % Price Change since this news event. The Volume Ratio is 4.99.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Merck’s KEYTRUDA® (pembrolizumab) Presented at 2015 ASCO Annual Meeting and Published in the New England Journal of Medicine
5/29/2015 2:05:00 PM - Business Wire
▼-1.86 % Price Change since this news event. The Volume Ratio is 4.97.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Merck Submits U.S. New Drug Application for Grazoprevir/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy, for Treatment of Chronic Hepatitis C Genotypes 1, 4, and 6 Infection
5/28/2015 4:30:00 PM - Business Wire
▼-1.24 % Price Change since this news event. The Volume Ratio is 2.51.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (pembrolizumab)
5/28/2015 8:30:00 AM - Business Wire
▼-0.19 % Price Change since this news event. The Volume Ratio is 1.29.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Merck Announces Third-Quarter 2015 Dividend
5/26/2015 1:31:00 PM - Business Wire
▼-0.15 % Price Change since this news event. The Volume Ratio is 3.07.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


SIMPONI® (golimumab) Gains Positive Opinion from Committee for Medicinal Products for Human Use (CHMP) for the Treatment of Non-Radiographic Axial Spondyloarthritis
5/26/2015 6:33:00 AM - PR Newswire
▼-0.71 % Price Change since this news event. The Volume Ratio is 1.86.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


MSD Receives Positive CHMP Opinion for Pembrolizumab for the Treatment of Advanced Melanoma
5/22/2015 7:12:00 AM - Business Wire
▼-1.90 % Price Change since this news event. The Volume Ratio is 1.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma
5/22/2015 7:12:00 AM - Business Wire
▼-1.90 % Price Change since this news event. The Volume Ratio is 1.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Erin Energy Announces Production Rate from the Oyo Field
5/18/2015 8:00:00 AM - Business Wire


Merck to Present at the UBS Global Healthcare Conference
5/18/2015 8:00:00 AM - Business Wire
▼-2.79 % Price Change since this news event. The Volume Ratio is 0.88.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck’s Rapidly Expanding Immuno-Oncology Research Program for KEYTRUDA® (pembrolizumab) to be Presented
5/13/2015 5:00:00 PM - Business Wire
▼-0.49 % Price Change since this news event. The Volume Ratio is 0.77.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day